Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc (NTRB) is a pharmaceutical innovator focused on transdermal drug delivery systems and abuse-deterrent technologies designed to enhance medication safety. This page serves as the definitive source for official company announcements, financial updates, and strategic developments.
Investors and industry stakeholders will find timely updates on AVERSA technology advancements, regulatory milestones, partnership agreements, and product pipeline progress. Our curated news collection ensures access to verified information directly impacting Nutriband’s market position and contributions to opioid safety solutions.
Key content includes earnings reports, intellectual property updates, manufacturing collaborations, and research breakthroughs. Bookmark this page to monitor Nutriband’s progress in developing transdermal therapies that address critical public health challenges while maintaining compliance with global regulatory standards.
Nutriband (NASDAQ: NTRB / NTRBW) announced a non-binding Letter of Intent dated Dec 18, 2025 to explore advanced technology collaboration with Qvanta Group of Companies.
The LOI contemplates joint evaluation of quantum‑ready AI simulation, secure high‑performance computing, and cybersecurity/data‑integrity frameworks to support Nutriband’s abuse‑deterrent pharmaceutical research and product development. The parties will emphasize regulatory compliance and data protection. The LOI is non‑binding and expressly states there is no assurance a definitive agreement or transaction will occur.
Nutriband (NASDAQ:NTRB) announced development of AVERSA™ FENTANYL, an abuse‑deterrent transdermal fentanyl system combining Nutriband’s AVERSA™ technology with Kindeva’s FDA‑approved fentanyl patch.
The company positioned this program in response to the U.S. Executive Order designating illicit fentanyl and core precursors as weapons of mass destruction (Dec 15, 2025), while stressing that FDA‑approved prescription fentanyl remains medically necessary. Nutriband cites ongoing abuse/accidental exposure risks and projects peak annual U.S. sales of $80M–$200M for AVERSA™ FENTANYL. The AVERSA™ IP portfolio includes patents issued in 46 countries.
Nutriband (NASDAQ: NTRB / NTRBW) announced that Chairman and Co-Founder Serguei Melnik will present at NobleCon21 — Noble Capital Markets' 21st Emerging Growth Equity Conference in Boca Raton, FL on December 3, 2025 at 9:30 AM ET.
Interested investors may register at a discounted rate using code NTRBNOBLECON. A high-definition webcast will be posted the following day on nobleconference.com and channelchek.com and archived for 90 days.
Nutriband develops transdermal pharmaceuticals; its lead program is an abuse-deterrent fentanyl patch using AVERSA™ technology.
Nutriband (NASDAQ:NTRB) received final meeting minutes from a Sept 18, 2025 virtual face-to-face meeting with the US FDA regarding its lead product AVERSA™ FENTANYL, an abuse-deterrent fentanyl transdermal system. FDA confirmed the regulatory pathway as a 505(b)(2) NDA and provided CMC feedback on registration batch plans, manufacturing process validation, product specifications, stability testing, and planned Category 1 in vitro manipulation/extraction studies. Nutriband is incorporating FDA guidance as it advances toward an IND filing to support a Human Abuse Potential (HAP) clinical study. The company partners with Kindeva and cites a peak US sales potential of $80M–$200M. Nutriband holds patents in 46 countries.
Nutriband (NASDAQ: NTRB / NTRBW) announced that co-founder Gareth Sheridan has returned as CEO effective October 27, 2025. From August 10 to October 27, co-founder and chairman Serguei Melnik covered CEO duties.
Mr. Sheridan will lead the company through the remainder of 2025 toward a targeted NDA filing in 2026 for AVERSA FENTANYL, an abuse‑deterrent transdermal fentanyl patch. Management cites a Health Advances market analysis estimating peak U.S. sales of $80M–$200M. The AVERSA technology is protected by patents in 46 countries.
Nutriband (NASDAQ:NTRB / NTRBW) announced on October 10, 2025 that its 4P Therapeutics subsidiary signed an agreement with Brand Institute to develop the worldwide commercial brand name and visual identity for its lead product, the development-named AVERSA™ FENTANYL, an abuse-deterrent fentanyl transdermal system using AVERSA™ technology.
Brand Institute will provide naming and identity services and regulatory support via its Drug Safety Institute, leveraging prior experience with drug-name approvals and regulatory naming guidance.
Nutriband (NASDAQ:NTRB) filed a provisional patent application with the USPTO on October 8, 2025 to strengthen intellectual property covering its AVERSA™ transdermal abuse deterrent technology. The filing targets improved aversive formulations and coating application methods designed to enhance deterrence for patches containing opioids and stimulants.
The company notes AVERSA is already covered by issued patents in 46 countries and says conversion to a non‑provisional application and a subsequent patent grant could extend U.S. patent protection (statutory term starts from the non‑provisional filing date).
Nutriband (NASDAQ: NTRB / NTRBW) will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025. Chairman Serguei Melnik will deliver a formal presentation including a fireside Q&A at 3:00 PM Eastern, with live questions from the virtual audience.
Registered, qualified investors may request scheduled 1x1 meetings with management by contacting Giorgia Pigato at Noble Capital Markets. The live webcast will be available via Channelchek and will be archived on the company website and Channelchek for 90 days. Registration for the live presentation is free for attendees.
Nutriband Inc. (NASDAQ:NTRB) has announced its participation in the upcoming MicroCap Rodeo Conference in New York City on September 25, 2025. Company Chairman Serguei Melnik will deliver a presentation at 10:00 AM, focusing on operational highlights, growth initiatives, and the company's AVERSA platform technology.
The presentation will be available via live webcast, and management will conduct one-on-one meetings with approved investors. Interested parties can register for the virtual presentation through the conference website at www.microcaprodeo.com.
Nutriband (NASDAQ:NTRB) reported strong Q2 2025 financial results, with revenue reaching $1,289,884, marking a 50.87% increase year-over-year. The company maintains a robust cash position of $6.9 million, with total assets of $10.17 million and stockholders' equity of $8.5 million.
The company is advancing its lead product, AVERSA Fentanyl, with a scheduled Type C meeting on September 18th. Notably, the NDA filing will require only a single phase 1 Human Abuse Potential study, without the need for Phase 2 or 3 trials. Market analysis projects potential peak annual sales of $80-$200 million for AVERSA Fentanyl and up to $130 million for AVERSA Buprenorphine.
FAQ
What is the current stock price of Nutriband (NTRB)?
What is the market cap of Nutriband (NTRB)?
